Cytokinetics (CYTK) investor relations material

Commercial launch and product differentiation

• MYQORZO, a cardiac myosin inhibitor, received FDA and China approval at the end of 2025 and launched in the US in early 2026, with European launch preparations underway.

• Differentiation centers on rapid symptom improvement, flexible titration, and no heart failure hospitalizations linked to EF lowering in trials.

• Over 125 US sales reps focus on velocity accounts (750 prescribers covering 80% of the market) aiming for >50% new-to-brand share in phase I, with phase II targeting broader cardiologist engagement.

• Medicare covers over 60% of the market, with reimbursement nearly at parity with CAMZYOS; commercial access is ramping up, supported by bridge programs.

• MAPLE data has been filed to update the label, expected to reduce payer restrictions and accelerate broader adoption.

Market access, reimbursement, and international expansion

• Commercial access is expected to reach parity with CAMZYOS by Q4 2026, with bridge programs supporting patients during coverage reviews.

• In Europe, launch begins in Germany in Q2 2026, with additional markets by year-end and full Western European rollout in 2027; pricing is expected at 15–20% of US levels.

• European market opportunity mirrors the US in patient numbers, but reimbursement is country-specific, requiring tailored launches.

• European operations are lean, leveraging US resources and focusing on cost efficiency.

• MFN/Guard Model policy is being monitored, but current launch plans remain unchanged as potential impact is expected to be manageable.

Clinical development and upcoming catalysts

• ACACIA-HCM phase III data readout for non-obstructive HCM is expected in Q2 2026, with full results likely presented at ESC in August.

• The trial is powered for a five-point KCCQ change and 1.0 peak VO2 improvement; statistical significance on both endpoints is the goal, but totality of evidence will guide regulatory discussions.

• MAPLE data is anticipated to influence treatment guidelines, potentially elevating CMIs from last-line to higher in the treatment hierarchy.

• COMET-HF phase III trial for omecamtiv is ongoing, with recruitment progressing and China sites opening soon; timeline for readout will be clearer later in 2026.

• Ulacamten is in early-stage trials for HFpEF, with preliminary results possible by year-end.